Searched for
ONGLYZA
MNC pharma companies: Time to take a re-look? 8 pharma stocks, 5 with an upside of up to 34%Some time back an MNC pharma firm announced the divestment of one of its businesses in India. Another sold one of its plants. Now, with the...- MNC pharma: Time to re-look at them without bias? 8 MNC pharma stocks, 5 with an upside potential of 15 to 52%While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that h...
- MNC pharma: Time to relook at them? 8 pharma stocks, 4 with an upside potential of between 16 and 47%In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of gl...
- Be bullish, just manage risks & desire; 5 midcap stocks for long term investorsIn a bullish market many things change and one of them is the relationship between opportunity and challenges. Given the way markets are pa...
- Indian companies have made a comeback. Will MNCs be able to do it ? 7 MNC pharma stocks with upside potential of up to 21%While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having...
- Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of thes...
- For calibrating and diversifying risks? 6 midcap stocks from different sectors with the right financial matrixAs the Dalal street continues to be in party mode, staying bullish would appear to be the most logical thing at this point of time. Why fig...
- Glenmark gets USFDA nod to market generic diabetes drugThe company has received final approval from the US Food & Drug Administration (US FDA) for Saxagliptin Tablets (2.5 mg and 5 mg), the gene...
- Glenmark gets USFDA nod for generic diabetes drugGlenmark Pharmaceuticals Inc, USA, a unit of the company, has received tentative approval from the US Food & Drug Administration (US FDA) f...
- Glenmark gets USFDA's tentative nod for Saxagliptin tabletsAccording to IMS Health sales data for the 12-month period ending April 2017, the Onglyza tablets, 2.5 mg and 5 mg market achieved annual s...
- India rejects compulsory license application of Lee Pharma against AstraZeneca’s SaxagliptinThe Indian Patent Office has rejected the application of Lee Pharma for a compulsory license on AstraZeneca’s anti-diabetes drug saxaglipti...
- India rejects licence plea for AstraZeneca's anti-diabetic drugThe Indian patent office has rejected Hyderabad-based Lee Pharma's application for a compulsory licence on AstraZeneca's anti-diabetic medi...
- British drug maker AstraZeneca may launch innovative drugs in IndiaBritish drug maker AstraZeneca is betting big on Asia including emerging markets such as India where it plans to introduce innovative produ...
- India rejects Lee Pharma’s compulsory licence pleaIndia has decided against giving the compulsory licence for Anglo-Swedish drugmaker AstraZeneca’s key antidiabetes compound Saxagliptin.
- Fed cheer! Sensex up over 200 points, Nifty above 8,400; Nestle down 2%, Gati surges 7%, Essar Oil 3%Sensex surged as much as 156 points in trade on Thursday, led by gains in HDFC, Maruti Suzuki, L&T, RIL and Infosys.
- Twelve stocks in focus in Thursday's tradeIndian markets are expected to trade higher. Here is a list of twelve stocks which are likely to remain in focus today.
- High Court rejects AstraZeneca’s diabetes drug pleaThe Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabadbased Lee Pharma from making copies of its anti-diabetes drug Ongly...
- Lee Pharma wants licence for AstraZeneca's diabetes drugLee Pharma filed the application on June 29 to make a generic version of the patented drug, marketed as Onglyza, under Section 84 of the Pa...
- AstraZeneca, Dr Reddy's ink diabetes drug distribution pactBoth Riax and Riax M are trademarks of the AstraZeneca group. Dr Reddy's Laboratories will be distributing the two drugs in India.
- Bristol-Myers Squibb to acquire Amylin for USD 5.3 billionBristol-Myers Squibb will acquire drug maker Amylin for USD 5.3 billion, a move that will strengthen its position in the diabetic medicines...
Load More
